Comparative Pharmacology
Head-to-head clinical analysis: PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE versus TRASICOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE versus TRASICOR.
PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE vs TRASICOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propranolol is a nonselective beta-adrenergic receptor antagonist that blocks beta-1 and beta-2 receptors, decreasing heart rate, myocardial contractility, and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water.
Non-selective beta-adrenergic antagonist with intrinsic sympathomimetic activity (partial agonist) at beta-1 and beta-2 receptors, reducing heart rate, myocardial contractility, and blood pressure.
Oral: 1 tablet (propranolol 40 mg / hydrochlorothiazide 25 mg) twice daily or as needed to control blood pressure; maximum propranolol 320 mg/day.
20-40 mg orally three times daily, increased to 80-160 mg daily if needed; maximum 320 mg/day.
None Documented
None Documented
Propranolol: 3-6 hours (terminal) with significant interindividual variability; prolonged in hepatic impairment (up to 11 hours). Hydrochlorothiazide: 6-15 hours (terminal); prolonged in renal impairment (creatinine clearance <30 mL/min).
Terminal elimination half-life is approximately 8-12 hours in patients with normal renal function; may be prolonged in renal impairment, requiring dose adjustment.
Propranolol: <1% unchanged in urine; extensively metabolized in liver, metabolites (4-hydroxypropanolol and others) excreted renally (90%) and fecally (10%). Hydrochlorothiazide: >95% renally excreted unchanged; negligible biliary/fecal elimination.
Renal excretion of unchanged drug and metabolites accounts for approximately 80% of elimination, with about 20% appearing as unchanged drug; biliary/fecal excretion accounts for the remaining 20%.
Category C
Category C
Beta-Blocker
Beta-Blocker